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Abstract 
Tumor cells corrupt surrounding normal cells instructing them to support proliferative, 
pro-angiogenic and immunosuppressive networks that favor tumorigenesis and 
metastasis. This dynamic cross-talk is sustained by a range of intracellular signals and 
extracellular mediators produced by both tumoral and non-tumoral cells. Galectins -
whether secreted or intracellularly expressed- play central roles in the tumorigenic 
process by delivering regulatory signals that contribute to reprogram fibroblasts, 
endothelial and immune cell programs. Through glycosylation-dependent or 
independent mechanisms, these endogenous lectins control a variety of cellular events 
leading to tumor cell proliferation, survival, migration, inflammation, angiogenesis and 
immune escape. Here we discuss the role of galectin-driven pathways, particularly those 
activated in non-tumoral stromal cells, in modulating tumor progression. 
 
Key words: Galectins / Tumor microenvironment / Fibroblasts / Endothelial Cells/ 
Immune Cells 
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1. Introduction 
The tumor microenvironment (TME) includes a diversity of cell types such as 
fibroblasts/myofibroblasts, vascular endothelial cells (ECs), lymphatic endothelial cells 
(LECs) and immune/inflammatory cells [1]. These cells induce tumorigenesis by 
controlling angiogenesis, inflammation and immune escape through the coordinated 
action of soluble mediators, including cytokines, chemokines and growth factors. 
Interestingly, multifunctional cytokines such as transforming growth factor-1 (TGF-
1), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) may 
concurrently affect fibroblast, endothelial and immune cell programs that coordinately 
sustain tumor growth [2,3]. In this way, non-tumor cells can profoundly affect the 
tumorigenic process by conditioning the associated microenvironment through a limited 
number of 'multitask' signaling molecules that facilitate tumor survival, proliferation, 
and metastasis [3]. 
 Galectins, a family of glycan-binding proteins with affinity for N-
acetyllactosamine (LacNAc; Gal1-4GlcNAc)-containing glycoconjugates, have broad 
influence on fibroblast, vascular and immune cell biology [4-7]. From a structural 
viewpoint, these endogenous lectins display at least one carbohydrate recognition 
domain (CRD) in a single polypeptide chain that recognizes specific glycans on a 
variety of cell surface receptors and the extracellular matrix (ECM). Whereas mono-
CRD (proto-type) galectins, including galectin (Gal)-1, -2, -5, -7, -10, -11, -13, -14 and 
-15, occur as biologically active monomers or homodimers, bi-CRD (tandem-repeat) 
galectins (Gal-4, -6, -8, -9, 12) share two distinct CRDs connected by a linker peptide. 
On the other hand, Gal-3 -the only representative member of the chimera galectin-type 
subfamily- is composed of an N-terminal collagen-like domain and a C-terminal domain 
containing a single CRD. In most human cancers, altered (up- or down-regulated) 
expression of galectins correlates with poor clinical outcome and acquisition of 
metastatic phenotype [8]. Through glycosylation-dependent or -independent 
mechanisms these endogenous lectins have been shown to play key roles in tumor 
growth, homotypic and heterotypic cell aggregation, survival, migration, angiogenesis, 
lymphangiogenesis and immune escape [6,8,9]. Galectins in the TME have been shown 
to play key roles in tumor progression. In breast cancer, high levels of Gal-1 expression 
in stromal cells were observed in invasive carcinoma compared to carcinoma in situ, 
which showed positive correlation with TNM stage and axillary lymph node metastasis 
[10]. In this sense, Gal-1-positive stroma is preferentially found in triple negative and 
human epidermal growth factor receptor 2 (HER2)-positive breast tumors and correlates 
with epidermal growth factor receptor (EGFR)-positive, Ki67-positive cells and 
mutated p53 [11]. Here we discuss the role of galectins, particularly those synthesized 
and released by non-tumoral stromal cells such as fibroblasts, endothelial and immune 
cells in shaping the TME (Fig. 1). 
 
2. Galectins from fibroblasts 
In the TME, fibroblasts and myofibroblasts are collectively designated as 
carcinoma-associated fibroblasts (CAFs). CAFs promote tumor growth, invasion and 
angiogenesis and produce ECM, proteinases, cytokines, chemokines and growth factors 
[12-14]. Myofibroblasts are -smooth muscle actin (-SMA)-positive fibroblasts, a 
hallmark of activated fibroblasts [15,16]. Various cell types such as resident normal 
fibroblasts, ECs, pericytes, smooth muscle cells, pre-adipocytes and bone marrow-
derived progenitors, such as fibrocytes and mesenchymal stem cells can generate tumor-
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promoting myofibroblasts [17-19]. Moreover, soluble factors secreted by CAFs can 
promote tumor growth and metastasis through diverse mechanisms [20,21]. 
Recently, CAFs have been postulated to induce intratumoral fibrosis as a result 
of the deposition of a cross-linked collagen matrix, and such fibrotic process has been 
shown to exert mechanical forces creating a biochemical milieu that shapes intratumoral 
immunity and influences tumor cell metastatic behavior. Hence, metastasis results from 
a change in the type of stromal collagen cross-link, and fibrosis and inflammation 
perpetuate each other through proteolytic and chemotactic mediators released into the 
tumor stroma [22]. 
 
2.1 Galectin-1 in fibroblasts 
Gal-1 was the first galectin cloned from fibroblasts [23], and its accumulation in 
the TME surrounding thyroid [24], head and neck [25], colon [26], and prostate 
carcinoma [27] has been well documented. In ovary carcinoma, Gal-1 preferentially 
expressed in contiguous peritumoral fibroblasts. Conditioned medium (CM) obtained 
from ovary carcinoma cells induced increased Gal-1 expression in fibroblasts [28]. 
Downregulation of Gal-1 secretion by fibroblasts decreased MMP-2 expression in 
ovarian cells, suggesting that this lectin might affect the invasive capacity of tumor cells 
[29]. In head and neck squamous carcinoma, upregulation of Gal-1 by -SMA-positive 
CAFs correlated with known poor-prognosis factors [30]. In oral squamous cell 
carcinoma, Gal-1 overexpression has been associated with fibroblast activation: 
exogenously-added Gal-1 stimulated transdifferentiation of normal fibroblasts (NFs) to 
myofibroblasts, while Gal-1 knockdown normalized CAFs upon activation (Fig. 2). 
Conditioned medium from Gal-1 knockdown CAFs significantly inhibited oral 
squamous tumor cell migration and invasion, and down-regulated the expression of 
monocyte chemotactic protein-1 (MCP-1). Notably, Gal-1 knockdown in CAFs 
significantly inhibited CAF-induced tumor growth and intravasation in vivo when 
fibroblasts were co-inoculated with oral squamous cell carcinoma cells in nude mice 
[31] (Fig. 2). In co-cultures of hypopharyngeal carcinoma cells and fibroblasts, 
increased intracytoplasmic staining for Gal-1 and fibronectin (FN) was detected in 
fibroblasts, which secreted both proteins to the ECM [32] (Fig. 2). In gastric tissues, 
CAFs exhibited strong expression of Gal-1, and co-cultures of Gal-1 knockdown CAFs 
with gastric cancer cells showed inhibition of tumor cell migration and invasion as 
compared with co-incubation with Gal-1-sufficient control CAFs [33]. Expression of 
Gal-1 in cell lysates and CM was higher in gastric CAFs than in NFs, and exogenous 
Gal-1 stimulated NFs transformation into CAFs in a dose-dependent manner. Moreover, 
CM from Gal-1-positive CAFs promoted gastric cancer cell migration and invasion, an 
effect that was inhibited when CAFs were pretreated with Gal-1 siRNA [34]. 
In pancreatic carcinoma, strong Gal-1 immunostaining was observed in CAFs of 
the tumor ECM in comparison to the normal pancreatic stroma [35]. In fact, Gal-1 has 
been proposed to be one of the main factors that modulate the pancreatic TME, 
characterized by abundant stromal desmoplasia, a fibroinflammatory reaction composed 
of a dense ECM, and immune, endothelial and stellate (resident fibroblasts) cells. 
Normal pancreatic stellate cells (PSCs) are star-shaped fibroblasts, usually activated 
from their quiescent phenotype into myofibroblast-like cells in response to pancreatic 
injury. Gal-1 is strongly expressed in activated PSCs, and recombinant Gal-1 increased 
their proliferation favoring the activation of relevant signaling pathways including 
activating protein-1 (AP-1), extracellular-regulated kinase-1/2 (ERK1/2), c-Jun N-
terminal kinase (JNK) and nuclear factor-kappa B (NF-B) as well as the production of 
MCP-1, cytokine-induced neutrophil chemoattractant-1 (CINC-1) [36] and collagen 
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[37]. Gal-1 is expressed and released by activated PSCs, enhancing pancreatic cancer 
cell proliferation and infiltration in co-cultured invasion assays. Interestingly, both 
platelet-derived growth factor (PDGF) and transforming-growth factor-1 (TGF-1) 
promoted Gal-1 expression in cultured PSCs [38]. Endogenous Gal-1 in PSCs was 
found to be upregulated by TGF-1, inducing MMP2/ MMP9 and invasion of tumor 
pancreatic cells. In fact, in mouse xenografts, a strong signal for Gal-1 was detected in 
the TME when malignant PSCs were implanted in the presence of tumor cells as 
compared to tumors derived from injection of normal PSCs and tumor cells [39]. 
Genetic ablation of Gal-1 in a mouse model of pancreatic cancer suppressed tumor 
progression by reducing fibroblast activation, and Gal-1 down-regulation in CAFs 
altered the Hedgehog signaling pathway [40]. In liver tissues, proteomics of cellular and 
secreted proteins of normal (quiescent) and activated rat hepatic stellate cells (HSCs) 
showed up-regulation of Gal-1 upon cellular activation [41]. Expression of this lectin 
was upregulated in activated rat HSCs and in liver fibrosis and promoted higher 
proliferation and migration of activated HSCs through an ERK1/2 signaling pathway 
[42]. 
In human breast cancer, positive Gal-1 expression in CAFs correlated with 
enhanced regional lymph node metastasis [43]. Silencing Gal-1 in human breast CAFs 
markedly reduced the expression of α-SMA, fibroblast activation protein (FAP), and 
FN, while transfection with Gal-1 in NFs dramatically increased the expression of α-
SMA, FAP, and FN. Moreover, CM from CAFs induced the migration and invasion of 
human breast cancer cells and TGF-β1 secreted by breast cancer cells induced Gal-1 
expression, transdifferentiation and MMP-9 secretion in NFs [44]. 
Fibroblasts differentiation into myofibroblasts driven by TGF-β1 was 
accompanied by up-regulation of Gal-1 via phosphatidylinositide 3-kinase (PI3K)/AKT 
and p38 MAPK activation; Gal-1 knockdown inhibited TGF-β1-induced fibroblast 
differentiation (Fig. 2). Moreover, Gal-1 up-regulation -in the absence of TGF-β1 
treatment- triggered FN and α-SMA expression [45]. In addition, in gastric tumors, Gal-
1 knockdown in NFs abolished TGF-β-induced α-SMA expression. Accordingly, Gal-1 
promoted TGF-β-driven NF transformation into CAF by enhancing Smad2 activation 
[34]. Thus, galectins shape the TME, at least in part, by modulating fibroblast signaling 
programs, through autocrine or paracrine mechanisms. 
 
2.2 Galectin-3 in fibroblasts 
Expression and secretion of Gal-3 has been well documented in NFs [46-50] and 
its silencing at the genetic level led to inhibition of fibroblast proliferation [51]. 
Similarly, Gal-3 knockout in mouse embryonic fibroblasts (MEFs) or Gal-3-depletion in 
human skin NFs decreased cell proliferation and increased premature senescence, 
highlighting a role for Gal-3 in senescence regulation [52]. As a result of their cross-talk 
with tumor cells, NFs inhibit early proliferation and motility of malignant cells. In this 
sense, co-cultures of NFs and prostatic PC3 tumor cells revealed that Gal-3 was one of 
the eight highly secreted proteins to the CM, contributing to inhibition of tumor cell 
proliferation and motility [50] (Fig. 2). 
Interestingly, Gal-3 expressed by myofibroblasts also contributed to 
inflammatory responses. In fact, in fibrotic liver, Gal-3 exerts growth-promoting effects 
on HSCs through ERK1/2 activation [42]. Disruption of Gal-3 gene suppressed 
myofibroblast activation and pro-collagen expression in vitro and in vivo, an effect that 
was prevented by adding exogenous Gal-3. Similarly, Gal-3 expression was upregulated 
in myofibroblasts during in vivo liver injury, and Gal-3 knockdown inhibited this effect. 
Moreover, TGF-β failed to transactivate Gal-3-deficient HSCs [53,54]. Likewise, TGF-
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β- and bleomycin-induced lung fibrosis was dramatically reduced in mice deficient in 
Gal-3, as revealed by reduced TGF-β–induced epithelial to mesenchymal transition 
(EMT), myofibroblast activation, and collagen production [55]. In intestinal tissues, 
Gal-3 from epithelial cells was identified as a strong activator of human colon NFs, 
inducing NF-B activation and interleukin-8 (IL8) secretion in primary intestinal 
fibroblasts and stimulating their migration. Likewise; in human intestinal fibroblasts, 
exogenous Gal-3 also induced IL-8 secretion, promoting inflammation [56,57]. 
Accordingly, this lectin also induced secretion of IL-6, granulocyte-macrophage colony 
stimulating factor (GM-CSF), CXCL8, and MMP-3 in fibroblasts, producing high 
secretion of tumor necrosis factor (TNF) and CCL2, CCL3, and CCL5 chemokines [58]. 
In rat cardiac NFs, exogenous Gal-3 induced cell proliferation, collagen production, and 
cyclin D1 expression [59], while in human corneal NFs this lectin induced up-regulated 
expression of -SMA and connective tissue growth factor (CTGF), a fibrosis-related 
growth factor [60] (Fig. 2). 
Pioneering experiments demonstrated that Gal-3 overexpression in NFs caused 
actin microfilament reorganization, anchorage-independent growth and morphological 
transformation in vitro, but not tumorigenicity in vivo, while Gal-3 transfection in 
fibrosarcoma cells resulted in increased lung metastases in mice [61] (Fig. 2). Thus, 
Gal-3 is a central player in fibroblast differentiation, inducing the conversion of NFs to 
myofibroblasts with up-regulation of -SMA [62], displaying multiple roles in different 
stromal cells [63,64]. In breast carcinoma, CAFs in the tumor stroma revealed positive 
staining for Gal-3, while Gal-3 expression in tumor stroma negatively correlated with 
patient prognosis [65,66]. 
In uterine carcinomas, Gal-3 was detected in single-cell suspensions of stromal 
CAFs from fresh tumor biopsies [67]. In thyroid tissues, Gal-3 mRNA was detected in 
stromal NFs with similar levels to those observed in normal thyroid tissues, follicular 
adenomas and carcinomas [68]. In gastric tissues, Gal-3 has been found in NFs of the 
submucosal layer [69], mediating cell activation and migration in the gastrointestinal 
tract [57]. Telomerase reverse transcriptase (TERT) mRNA was shown to be decreased 
in Gal-3 knockout MEFs, while Gal-3 mRNA was also reduced in TERT knockout 
MEFs, suggesting that Gal-3 and TERT regulate each other. Overexpression of TERT 
in human NFs increased cell proliferation, reducing p27
kip1
 (a senescence inducer) 
protein levels and senescence, while Gal-3 knockdown prevented these effects. Thus, 
Gal-3 from fibroblasts regulates TERT expression and function in cellular senescence, 
which was also observed in gastric cancer cells [70]. 
A critical TME factor is oxygen, and Gal-3 was one of the up-regulated genes in 
murine NFs under hypoxic conditions. A comparative analysis between wild-type and 
hypoxia-inducible factor 1α−/−  fibroblasts demonstrated that Gal-3 up-regulation under 
hypoxia was HIF-1α -dependent [71]. A HIF-1α-binding site in Gal-3 promoter was 
found in MEFs and in HeLa cervical cancer cells, and hypoxia induced Gal-3 mRNA, 
protein, and promoter activity in MEFs derived from wild-type mice but not in those 
from HIF-1−/− mice [72] (Fig. 2). Moreover, Gal-3 was found to be a key binding 
partner of K-Ras GTP protein. In Gal-3
-/- 
MEFs, marked reduction of K-Ras was found, 
and Gal-3 transfection increased K-Ras GTP activity. In fact, this lectin negatively 
regulated Let-7 miRNA expression in MEFs, leading to increased K-Ras expression 
[73], fuelling NF transformation. Thus, a coordinated network of galectins and their 
glycosylated ligands control fibroblast signaling in the TME. 
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3. Galectins in vascular and lymphatic endothelial cell compartments 
3.1 Galectin-1 in endothelial cells 
The role of galectins in vascular endothelium and tumorigenesis has been widely 
demonstrated [74]. Activated ECs synthesize high amounts of Gal-1 [75,76] and this 
lectin has been implicated in tumor angiogenesis [77]. Incubation of ECs with CM from 
prostate carcinoma cells augmented Gal-1 expression, an effect that was critical for 
tumor-EC adhesion [78]. Modulation of EC programs including EC proliferation, 
migration, and capillary-tube formation has been well documented in vitro and in vivo 
[77,79-81]. Noteworthy, Gal-1 may be synthesized or taken up by ECs to promote 
angiogenesis in an autocrine or paracrine manner [82]. Whereas Gal-1-N-glycan 
interactions in Kaposi´s sarcoma can link tumor hypoxia to vascularization through 
HIF-1-independent mechanisms [80], expression of this lectin involves HIF-1-
dependent pathways in the microenvironment of other tumor types including human 
renal carcinoma and acute myeloid leukemia [83,84]. Interestingly, in prostate cancer 
patients Gal-1 directly correlated with tumor vascularization and poor clinical outcome, 
and promoted vascularization independently of other pro-angiogenic factors [85]. This 
pro-angiogenic effect was mediated by direct interactions with neuropilin-1 (NRP-1) 
and/or VEGFR2 and involved signaling via ERK1/2 and AKT [79,86]. Remarkably, 
Gal-1-driven VEGFR2 phosphorylation was sustained even in the absence of the 
canonical ligand VEGF, suggesting the potential role of this lectin as a mechanism of 
resistance to anti-VEGF therapies. Blockade of Gal-1 using neutralizing mAb or 
disruption of specific ligands (complex N-glycan branching) by genetic ablation of the 
N-acetylglucosaminyltransferase V (MGAT5) converted refractory into anti-VEGF 
sensitive tumors [81]. In contrast, removal of 2,6-linked sialic acid from ECs by 
disruption of 2,6-sialyltransferase 1 (ST6GAL1) eliminated sensitivity to anti-VEGF 
mAb and favored tumor angiogenesis by unmasking Gal-1-specific glyco-epitopes [81] 
(Fig. 3). Notably, Gal-1 blockade also induced vessel normalization as revealed by 
pericyte coverage of ECs, reduction of tumor hypoxia and augmented influx of immune 
cells into the tumor parenchyma [81], suggesting a major role for this lectin in 
connecting ECs, pericytes and immune cell networks. Interestingly, genome-wide 
functional analysis recently identified Gal-1 as a pivotal regulator of lymphatic vascular 
growth and maintenance of the lymphatic endothelial phenotype via lectin interaction 
with VEGFR2 [87].  
 
3.2 Galectin-3 and -8 in endothelial cells 
Early studies demonstrated that Gal-3 induces EC tube formation and chemotaxis in 
vitro and in vivo in models of breast cancer [88]. In fact, Gal-3 has been proposed as a 
binding partner for aminopeptidase N/CD13 (APN), a Zn
2+
-dependent 
metalloexopeptidase in ECs [89]. Silencing Gal-3 markedly reduced VEGF-A and 
bFGF-mediated cell migration and angiogenesis in vitro and in vivo, suggesting that, in 
contrast to Gal-1, this lectin functions by regulating activity of pro-angiogenic ligands. 
Disruption of complex branched N-glycans in ECs lacking MGAT5 reduced Gal-3-
induced angiogenesis. Moreover, function-blocking mAbs against αvβ3 integrins 
markedly reduced Gal-3-induced angiogenesis [90]. Like Gal-1, Gal-3 also binds and 
activates VEGFR2 in ECs, inducing VEGFR2 phosphorylation. Knocking down Gal-3 
or MGAT5 reduced VEGF-A-mediated angiogenesis. Therefore, Gal-3 modulates EC 
biology by directly interacting with VEGFR2 N-glycans and increasing the angiogenic 
response to its canonical ligand [91] (Fig. 3). 
 Like Gal-1 and Gal-3, Gal-8 is one of the most prominent galectins found in ECs 
[76]. Either exogenously added or endogenously regulated, this two-CRD galectin 
  
 8 
promotes EC migration and capillary tube formation, and facilitates angiogenesis in 
vivo. Remarkably, activated leukocyte cell adhesion molecule (ALCAM/CD166) was 
identified as a specific Gal-8-binding partner in vascular ECs (Fig. 3), and anti-ALCAM 
blocking antibodies diminished Gal-8-induced angiogenesis [92]. Furthermore, Gal-8 
also bound to LECs and promoted lymphangiogenesis [93]. A mechanistic analysis 
revealed that Gal-8 induces lymphangiogenesis by interacting with podoplanin (PDPN) 
and α1β1 or α5β1 integrins in a VEGFR3-independent fashion. However, Gal-8 also 
potentiates VEGF-C-induced lymphangiogenesis in vitro and in vivo, through a 
mechanism involving PDPN/Gal-8/integrin interactions and potentiation of VEGFR3 
signaling [94] (Fig. 3). Thus, galectins, particularly Gal-1, -3 and -8, promote 
angiogenesis and lymphangiogenesis via interaction with a selected repertoire of 
glycosylated receptors on ECs and LECs. 
 
4. Galectins in immune cell compartments 
 
Galectins favor tumor growth by inhibiting immune surveillance through several 
mechanisms, including promotion of T-cell apoptosis, suppression of T-cell activation, 
shift toward an anti-inflammatory Th2 profile, expansion of Foxp3
+
 T regulatory cells 
(Tregs), differentiation of IL-27
+
 IL-10
+
 tolerogenic dendritic cells (DCs), inhibition of 
NK cell cytotoxicity, and polarization of macrophages toward an M2 phenotype 
[95,96]. These immunoregulatory pathways are summarized in Fig. 1. 
 
4.1 Galectin-1 induces T-cell apoptosis and shifts the balance toward a Th2 
cytokine profile 
In different cancer settings, Gal-1 has been proposed to induce T-cell death. 
Expression of this lectin correlated with the extent of tumor-induced T-cell death in 
both murine and human melanoma cells. In a melanoma model, Gal-1 blockade 
markedly enhanced tumor rejection by enhancing Th1 responses, suggesting that Gal-1 
contributes to tumor immune privilege by modulating T-cell survival and cytokine 
production [97]. In head and neck squamous cell carcinomas, Gal-1 overexpression 
inversely correlated with the number of infiltrating T cells and was an independent 
prognostic factor for shorter overall survival [98]. 
In neuroblastoma cells, Gal-1 acted as a pro-apoptotic soluble factor that 
compromised T-cell function. Inhibition of Gal-1 gene expression reduced primary 
tumor growth and prevented metastasis in a murine model. Splenocytes from mice 
inoculated with Gal-1-silenced neuroblastoma cells showed higher cytotoxic activity 
when compared with splenocytes from mice inoculated with Gal-1-overexpressing 
tumor cells. At the cellular level, tumor-derived Gal-1 impaired T-cell effector functions 
by promoting T-cell apoptosis, reducing IFN- secretion and decreasing T-cell 
recruitment to tumor parenchyma [99]. 
In Lewis lung carcinoma (LLC), tumoral Gal-1 was found to be more important 
than host Gal-1 in enhancing tumor growth and metastasis, through immune-mediated 
mechanisms. When wild-type or Gal-1 null mice were inoculated subcutaneously with 
control or Gal-1-silenced LLC cells, expression of tumor Gal-1, rather than that of the 
host, was essential for tumor growth and spontaneous metastasis. Lung metastasis was 
only found in mice bearing Gal-1-expressing tumors and not in mice bearing Gal-1-
silenced tumors. Increased apoptosis of CD8
+
- and CD4
+
-T cells was observed in the 
microenvironment of control versus Gal-1 knockdown tumors in both wild-type and 
Gal-1 null mutant mice. The effects of Gal-1 on tumor growth and metastasis were 
abrogated in immunocompromised mouse models, highlighting the critical role of 
immune cells as targets of the pro-tumorigenic effects of this lectin. In addition, more 
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viable CD4
+
 and CD8
+
 T-cells were detected in the hypoxic areas of Gal-1 knockdown 
compared to control Gal-1-sufficient tumors. In fact, intratumoral hypoxia augmented 
Gal-1 secretion and diffusion, which promoted T-cell apoptosis [100]. 
Interestingly, in co-cultures of primary human PSCs and T cells, overexpression 
of Gal-1 in PSCs induced T cell apoptosis while knockdown of Gal-1 in PSCs increased 
CD4
+
 T cell and CD8
+
 T cell viability. Supernatants from T cells co-cultured with Gal-
1-overexpressing PSCs increased the levels of Th2 cytokines (IL-4 and IL-5) and 
decreased the amounts of Th1 cytokines (IL-2 and IFN-). Thus, PSC-derived Gal-1 
induces T-cell apoptosis and contributes to Th2 cytokine shift, regulating PSC-
dependent immune privilege in the pancreatic TME [101]. A mechanistic analysis of 
Gal-1 effects revealed the ability of this lectin to selectively delete Th1 and Th17 
lymphocytes through differential glycosylation of these cells. In brief, Th1 and Th17 
cells share the repertoire of glycans that are important for Gal-1 binding and T-cell 
death. In contrast, Th2 cells are protected from Gal-1 through 2,6 sialylation of these 
cells [102]. Thus, Gal-1 impairs T-cell function by promoting T-cell apoptosis and 
modulating T helper cytokine balance. 
 
4.2 Galectin-1 promotes expansion of Foxp3
+
 and Foxp3
- 
regulatory T cells 
Inducible CD4
+
 regulatory T cells (iTregs) are generated outside the thymic 
compartment to regulate peripheral immune tolerance, whereas thymus-derived 
naturally occurring CD4
+
 regulatory T cells (nTregs) are generated within the thymus. 
Notably, iTregs may be divided into two subsets: the classical TGF-1-induced CD4
+
 
Foxp3
+
 Tregs and the CD4
+
 Foxp3
-
 type 1 regulatory T (Tr1) cells [103]. Upregulation 
of Gal-1 was evident in Foxp3
+
 Tregs compared to activated effector T cells at the 
mRNA level [104]. Garin and colleagues confirmed the abundance of Gal-1 protein in 
Foxp3
+
 Tregs and provided evidence of its contribution to the suppressive activity of 
these cells. Disruption of Gal-1 attenuated the inhibitory effects of human and mouse 
Foxp3
+
 Tregs, suggesting the involvement of this lectin in Treg-mediated 
immunosuppression [105]. In a breast cancer model, silencing tumor-derived Gal-1 
reduced the frequency of CD4
+
 CD25
+
 Foxp3
+
 Tregs within tumor, draining lymph 
nodes, spleen and lung metastases. Tregs isolated from mice bearing Gal-1-depleted 
tumors exerted poor immunosuppressive activity when co-cultured with conventional T 
cells. Considerable downregulation of linker of activated T cells (LAT) was detected in 
Tregs isolated from the metastatic lungs or from the tumor-draining lymph nodes of 
mice bearing Gal-1-deficient tumors, suggesting an association between Gal-1, LAT 
and the immunosuppressive activity of these cells [106]. 
Reed-Sternberg cells from classical Hodgkin lymphoma overexpressed Gal-1 
through an AP-1-dependent enhancer. In co-cultures of activated T cells and Hodgkin 
tumor cell lines, blockade of tumoral Gal-1 enhanced T-cell viability and restored the 
Th1/Th2 cytokine balance. In contrast, Gal-1 treatment of activated T cells favored 
secretion of Th2 cytokines and facilitated expansion of CD4
+ 
CD25
high
 Foxp3
+
 Tregs, 
protecting Reed-Sternberg cells from immune attack [107]. Of note, expression of Gal-1 
together with c-Jun contributed to delineate Hodgkin lymphoma from other lymphoma 
types [108]. On the other hand, Gal-1 binding to unpolarized activated T cells induced 
an immunoregulatory signature defined by IL-10, suggesting that this lectin also 
induces differentiation of Foxp3
-
 Tr1 cells. In fact, Gal-1 association with cell surface 
glycoproteins on CD4 T cells induced polarization toward an immunoregulatory Tr1 
phenotype characterized by IL-10 production through mechanisms involving IL-21 and 
the c-Maf and aryl hydrocarbon receptor (AHR) pathways [109]. Thus, Gal-1-glycan 
interactions foster differentiation of both Foxp3
+
 Tregs and Foxp3
-
 Tr1 cells. 
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4.3 Galectin-1 induces tolerogenic dendritic cells 
Soluble factors secreted by tumor cells or upregulated in the TME may instruct 
dendritic cells (DCs) to become tolerogenic and suppress T-cell responses. We 
demonstrated that DCs differentiated or matured in a Gal-1-enriched microenvironment 
acquired regulatory or tolerogenic signatures characterized by low expression of CD11c 
(mouse DCs) or CD1a (human DCs), high expression of CD45RB, phosphorylation of 
signal transducer and activator of transcription-3 (STAT-3) and secretion of IL-27 and 
IL-10. When transferred in vivo, these DCs promoted T-cell tolerance in antigen-
specific and cancer settings (particularly melanoma), generating an immunoregulatory 
circuit linking Gal-1, IL-27 and IL-10 [110]. Moreover, when mouse bone marrow-
derived DCs (BMDCs) were cultured in the presence of CM collected from Gal-1-
expressing neuroblastoma cells, lower expression of co-stimulatory molecules was 
detected on CD11c
+
 BMDCs. Thus, neuroblastoma-derived Gal-1 controls effector T 
cell responses indirectly via promotion of immature or tolerogenic DCs [99]. 
In lung cancer settings, Gal-1 also promoted tolerogenic DCs, which in turn 
favored the induction of Foxp3
+
 Tregs. Further examination of the mechanisms 
underlying these effects revealed the ability of this lectin to alter the function of DCs 
through an IL-10-dependent autocrine effect, regulated by the inhibitor of DNA binding 
3 (Id3) transcription factor [111]. Interestingly, recent studies showed that expression of 
the special AT-rich sequence-binding protein-1 (Satb1) chromatin organizer on tumor-
associated DCs controls their immunosuppressive activity through mechanisms 
involving Gal-1. Although Satb1 expression on wild-type DCs was sufficient to 
accelerate tumor growth when admixed in vivo with ovary cancer cells, this effect was 
abrogated when DCs lacked Gal-1 expression [112]. Moreover, Hsu and colleagues 
found that, in response to Gal-1, CAFs up-regulated expression of tryptophan 2,3-
dioxygenase (TDO2) and produced the tryptophan metabolite kynurenine that inhibited 
DC differentiation and induced lung cancer growth. These results demonstrate a critical 
role for Gal-1 in creating immunosuppressive microenvironments by linking lung 
cancer cells, CAFs and tolerogenic DCs [113]. 
 
4.4 Galectin-1 impairs NK cell function 
NK cells protect against early tumor formation through mechanisms involving 
cytotoxic activity against transformed cells and secretion of pro-inflammatory 
cytokines. In Kaposi´s sarcoma murine models, we demonstrated therapeutic benefits of 
a Gal-1–specific mAb through mechanisms involving inhibition of aberrant tumor 
angiogenesis and increased recruitment of NK cells [80]. Whereas no differences were 
found in the frequency of infiltrating B220
+
 B cells and F4/80
+ 
macrophages between 
xenografts treated with a Gal-1–specific mAb [114] or isotype control, Gal-1 blockade 
resulted in an increased percentage of tumor-infiltrating NK cells [80]. 
Furthermore, Baker and coworkers showed that glioblastoma cells suppress NK 
cell-mediated immune surveillance by overexpressing Gal-1. Conversely, Gal-1-
deficient glioma cells could be eradicated by host NK cells before the initiation of an 
antitumor T-cell response. Knocking down Gal-1 in glioma cells led to rapid 
accumulation of cytotoxic NK cells within the brain TME allowing complete tumor 
eradication in the absence of an ongoing anti-tumor T-cell response. In vitro, Gal-1-
deficient glioma cells were 3-fold more sensitive to NK cell-mediated tumor lysis than 
Gal-1 overexpressing tumor cells [115]. In fact, knocking down Gal-1 in glioma cells 
improved their inflammatory status leading to rapid recruitment of Gr-1
+
 CD11b
+
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myeloid cells and NK cells, inducing tumor clearance in mice lacking mature T- and B-
cells. Immunodepletion of Gr-1
+
 myeloid cells allowed growth of Gal-1-deficient 
glioma cells despite the presence of NK cells, thus demonstrating an essential role for 
myeloid cells in the clearance of Gal-1-deficient glioma [116]. Thus, NK cells as well as 
myeloid cells are essential targets of the immune inhibitory activity of Gal-1 in the 
TME. 
 
4.5 Galectin-1 contributes to the immunoregulatory and pro-tumoral activities of 
macrophages and myeloid-derived suppressor cells 
In addition to DCs, the TME is often infiltrated by other myeloid cells such as 
macrophages and myeloid-derived suppressor cells (MDSCs). Within the 
monocyte/macrophage compartment Gal-1 contributes to de-activation of these cells 
and polarization from an M1 pro-inflammatory toward an M2 anti-inflammatory 
phenotype [117-120]. This effect has been confirmed in microglia cells during central 
nervous system inflammation [121]. Recently, Van Woensel and coworkers showed that 
intranasal delivery of Gal-1 siRNA induced a remarkable switch in the TME 
composition, reducing macrophage polarization from M1 to M2 and inhibiting 
recruitment of monocytic MDSCs during glioblastoma multiforme progression [122]. In 
this sense, Gal-1 levels positively correlated with soluble CD163, a biomarker of M2 
macrophage activation in sera from multiple myeloma patients [123]. 
MDSCs are a heterogeneous population of immature cells shown to accumulate 
in the blood and TME of human and murine tumors, which can influence anticancer 
immunity by altering macrophage, NK cell and T-cell effector functions [124]. Two 
major MDSC subsets are recognized: granulocytic (Ly-6G
high
 CD11b
+
 Ly-6C
low
) and 
monocytic (Ly-6G
low
 CD11b
+
 Ly-6C
high
) MDSCs [125]. In ovarian cancer models, 
MDSCs and -T cells are major Gal-1 producers, contributing to systemic 
immunosuppression. This effect is tightly controlled by commensal microbiota, TLR5 
signaling and pro-inflammatory cytokines particularly IL-6 [126]. Briefly, TLR5-
dependent IL-6 production triggered by commensal bacteria favored malignant 
progression at extramucosal locations through mobilization of MDSCs and further 
expansion of -T cells producing high amounts of Gal-1 [126]. On the other hand, in 
glioblastoma models, Gal-1 silencing reduced recruitment of MDSCs to the TME 
highlighting a role for this lectin in modulating the function of this heterogeneous 
immunosuppressive cell population [120]. 
Finally, in patients with chronic lymphocytic leukemia (CLL), Gal-1 was found 
to be upregulated in nurse cells, a subset of non-tumoral CD68
+
 myeloid cells 
responsible of sustaining proliferation and survival of leukemic B cells. In co-cultures 
of nurse cells and CLL cells, this lectin augmented B-cell receptor signaling, providing 
an appropriate niche for tumor progression [127].  
 
4.6 Immunoregulatory effects mediated by Gal-3, -8 and -9 
Gal-3 has been shown to play key immunomodulatory roles promoting T-cell 
apoptosis and modulating T-cell receptor (TCR) signaling [128,129]. Extracellular Gal-
3 promotes apoptosis in both human and murine T cells upon binding to T-cell surface 
glycoproteins CD7 and CD29, providing an alternative mechanism by which cancer 
cells may evade immune responses [128]. Similarly, colorectal tumor-reactive T cells 
become apoptotic in response to Gal-3 signaling leading to enhanced tumor growth in 
vitro and in vivo [130]. Accordingly, a glycopeptide capable of binding Gal-3 inhibited 
Gal-3-mediated T-cell apoptosis and suppressed prostate cancer metastasis [131]. 
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Remarkably, human CD8
+
 tumor-infiltrating lymphocytes (TILs) from different 
solid tumors and ascites, but not CD8+ circulating T cells, showed impaired IFN-γ 
secretion following ex vivo restimulation. However, these cells evidenced enhanced 
IFN-γ production upon treatment with the saccharide N-acetyllactosamine (a galectin-
specific inhibitor) [132]. Furthermore, GCS-100, a modified polysaccharide pectin that 
interrupts Gal-3 signaling, as well as N-acetyllactosamine treatment promoted 
colocalization of the TCR with coreceptors CD8 or CD4 on the surface of TILs, by 
detaching Gal-3 from the cell surface and increasing TCR mobility [133]. More 
recently, Gal-3 has been shown modulate the availability of glycosylated soluble factors 
including IFN-γ, thus limiting T-cell infiltration and antitumor immunity [134]. Hence, 
administration of Gal-3 antagonists results in higher activation of the tumor infiltrating 
T cells with critical implications in tumor immunity. 
In pancreatic ductal carcinoma models, tumor-derived Gal-3 limited the 
expansion of plasmacytoid DCs. Interestingly, this lectin bound to antigen-experienced 
CD8
+
 T cells only in the TME, and Gal-3-deficient mice exhibited improved CD8
+
 T-
cell effector function and increased expression of several inflammatory genes. At the 
molecular level, Gal-3 bound to lymphocyte activation gene-3 (LAG-3), an inhibitory 
checkpoint molecule engaged by tumors to suppress CD8
+
 T-cell responses [135]. Thus, 
blocking Gal-3 may contribute to checkpoint blockade immunotherapies by interrupting 
LAG-3 function. On the other hand, Gal-9 has been shown to bind the T-cell 
immunoglobulin and mucin domain-3 (TIM-3) [136], another important checkpoint 
molecule, suggesting essential roles of individual galectins in engaging immune 
inhibitory receptors. 
In addition to its role in T-cell biology, Gal-3 expression has also been 
associated to macrophage polarization towards an M2 phenotype [137], as well as to 
inhibition of NK cell activity [138-140]. This lectin impairs NK cell functions through 
binding to the NKp30 receptor, thus allowing tumor cell evasion of NK cell attack 
[140]. Additionally, Gal-3 can impair NK cell activity by inhibiting interactions 
between NKG2D, an activating NK cell receptor and major histocompatibility complex 
class I-related chain A (MICA) [139], a ligand highly expressed on the surface of 
tumors, endothelial and lymphoid cells [139,141]. 
Remarkably, Gal-8 promotes the differentiation of Foxp3
+
 Tregs through 
modulation of TGF-β1 and IL-2 signaling [142], in addition to its documented roles in 
tumor angiogenesis [92] and migration [143], emphasizing the potential role of this 
lectin in tumor immunosuppression. Moreover, Dardalhon and colleagues found that 
activation of the Gal-9/Tim-3 pathway increased the number of CD11b
+
 Ly-6G
+
 
granulocytic MDSCs, which negatively controlled T-cell responses in vivo [144]. 
Furthermore, Gal-9 promoted Treg differentiation and stability through binding to 
CD44 and modulation of TGF-1-driven SMAD signaling [145]. More recently, in the 
context of pancreatic adenocarcinoma, Gal-9 has been shown to interact with Dectin-1 
on the surface of tumor-associated macrophages reprogramming these cells toward an 
immunosuppressive phenotype. Blockade of the Dectin 1/Gal-9 axis reinvigorated CD4
+
 
and CD8
+
 T cell responses and contributed to eradicate pancreatic tumors in different 
models [146]. Strikingly, granulocytic MDSCs infiltrating pancreatic ductal 
adenocarcinoma were found to be the main source of Gal-9, thus emphasizing the 
relevance of non-tumoral galectins in tumor progression [146]. Thus, different members 
of the galectin family may influence tumor immunity by modulating lymphoid and 
myeloid programs. 
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Conclusions 
 
In this review we focus on the pro-tumorigenic roles of galectins in the TME. First, we 
discuss the role of galectins within the fibroblast compartment. An emerging hypothesis 
proposes fibroblasts as initiators of cancer pathogenesis, due to their inherent 
heterogeneity, plasticity and function, which enable them to modulate normal and tumor 
epithelia. While NFs from disease-free tissues inhibit tumor growth, CAFs favor tumor 
progression as they secrete soluble factors that enhance tumor cell proliferation, 
angiogenesis and immunosuppression. CAFs can also suffer vasculogenic mimicry, as 
tumor cells do, and may promote angiogenesis and tumor-immune escape by releasing a 
variety of pro-angiogenic and immunosuppressive mediators including galectins. 
Second, we discuss the role of galectins, particularly Gal-1, Gal-3 and Gal-8 in 
modulating angiogenesis and lymphangiogenesis, effects that ultimately lead to tumor 
progression. Finally, we analyze the role of galectins in modulating immune signaling 
programs influencing T cells, NK cells, DCs, macrophages and MDSCs. Particularly we 
highlight the role of immune cells, both of lymphoid and myeloid origin, as major 
galectin sources and regulators of local and distant tumor growth. Hence, galectin-
dependent circuits involving CAFs, ECs, LECs and immune cells, cooperate with tumor 
cells to create hostile microenvironments that sustain tumor growth and metastasis. 
Thus, targeting selected members of the galectin family in both tumoral and non-tumor 
cells, may contribute to extinguish tumor progression by controlling abnormal 
vascularization, thwarting immunosuppression and preventing metastasis. 
 Noteworthy, most experimental models used to study galectins in cancer show 
several limitations precluding clear discrimination of the role of tumor-derived galectins 
versus those expressed in non-tumoral cells within the TME. Most in vivo studies have 
been accomplished in galectin-deficient mice or wild-type mice [80-82], which have 
been inoculated with syngeneic tumor cells expressing normal, upregulated or 
downregulated galectin levels. However, the contribution of each cellular compartment 
to the overall galectin effects has not yet been elucidated. In this regard, some in vivo 
models including selective immunodepletion of myeloid cell populations in 
immunodeficient mice (with impaired T- and B-cells) inoculated with Gal-1-deficient 
tumor cells were used to dissect the role of individual immune cell types as selective 
targets of this protein [116]. Further studies are awaited to dissect the role of galectins 
in the TME using conditional knockout selectively overexpressing or eliminating 
galectins in different TME compartments [147], including CAFs, pericytes, ECs, innate 
immune cells (macrophages, neutrophils, DCs, MDSCs) as well as adaptive immune 
cells (T cells, B cells). Furthermore, the use of clinically-relevant, genetically 
engineered mouse models crossed with galectin-deficient strains will be important to 
faithfully recapitulate clinical features of the human neoplastic disease. 
 Different galectin blocking compounds have been tested in vitro and/or in vivo, 
including specific anti-galectin neutralizing antibodies [80,81]. Moreover, glycan-based 
galectin inhibitors have also been investigated and proved to be promising low-
nanomolar galectin antagonists [148-153]. Furthermore, plant pectins and 
galactomannans have also shown antitumoral activities by virtue of their ability to bind 
galectins [154,155]; yet recent studies demonstrated that these naturally-occurring 
saccharides exhibit low inhibitory potency towards galectins CRDs [156]. Peptide-
based galectin inhibitors such as anginex [77,157] or its derivatives 6DBF7 [158] or 
OTX008 [159,160] have also been shown to inhibit galectin functions including tumor 
angiogenesis and cell migration. Further studies should be aimed at evaluating this 
  
 14 
portfolio of anti-galectin compounds in pre-clinical settings and clinically-relevant 
tumor models. 
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Figure Legends 
 
Figure 1: Functions of galectins in the tumor microenvironment. Different effects of 
galectins, particularly those produced by non-tumoral cells are illustrated. Cancer-
associated fibroblasts (CAFs) express and secrete galectins (e.g. Gal-1 and Gal-3) which 
control tumorigenic events including tumor cell migration, proliferation, angiogenesis, 
immunosuppression and metastasis, and promote expression of metalloproteinases (e.g. 
MMP-2), chemokines (e.g. MCP-1/CCL-2) and pro-angiogenic factors (e.g. VEGF). 
Endothelial cells (ECs) also synthesize galectins which contribute to tumor progression 
through different mechanisms. Gal-1, -3- and -8 control both vascular EC and lymphatic 
EC (LEC) programs, and modulate angiogenesis and lymphangiogenesis by co-opting 
different signaling pathways and glycosylated receptors, including VEGFR2, VEGFR3, 
neuropilin-1 (NRP-1) and podoplanin. Innate and adaptive immune cells, including 
myeloid-derived suppresssor cells (MDSCs), -T cells, regulatory T cells (Tregs), 
tolerogenic dendritic cells (DCs), macrophages and myeloid-derived nurse-like cells can 
influence tumorigenic programs via galectin-dependent circuits that foster 
immunosuppressive TME. The collective action of galectins and their specific glycans, 
modulating fibroblast, vascular EC, LEC and immune cell compartments, contribute to 
reprogram the TME by controlling angiogenesis, immunosuppression and metastasis. 
Abbreviations: α-SMA: -smooth muscle actin; MCP-1/CCL2: monocyte chemotactic 
protein-1; MMP-2: matrix metalloproteinase-2; NRP-1: neuropilin-1; VEGF: vascular 
endothelial growth factor; VEGFR2: vascular endothelial growth factor receptor-2; 
FGFR: fibroblast growth factor receptor; ALCAM (CD166): activated leukocyte cell 
adhesion molecule; IL-6: interleukin 6. 
 
Figure 2: Galectin functions in tumor-associated fibroblasts. A, Gal-1 in 
tumorigenesis: Exogenous Gal-1 induces normal fibroblasts (NFs) transdifferentiation 
to cancer-associated fibroblasts (CAFs). CAFs overexpress and secrete Gal-1, which 
remains associated to the extracellular matrix (ECM). Transfection of Gal-1 gene 
(Lgals1) in NFs increases the expression of -smooth muscle actin (α-SMA), fibroblast 
activation protein (FAP) and fibronectin (FN) inducing a CAF phenotype. Conditioned 
medium (CM) obtained from CAFs promotes tumor cell migration and invasion, and in 
vivo metastasis. CM obtained from Gal-1-transfected NFs induces tumor cell migration 
and invasion. Co-cultures of tumor cells and CAFs stimulated in vitro tumor cell 
migration and invasion, and in vivo metastasis. TGF-β1 induces Gal-1 expression in NFs 
and fibroblast transdifferentiation. B, Gal-3 in tumorigenesis: Co-cultures of tumor 
cells and NFs show increased Gal-3 secreted to the CM, which inhibits tumor cell 
proliferation and motility. Exogenous Gal-3 induces transdifferentiation of NFs to 
CAFs, which in turn secrete high levels of this lectin. Gal-3 transfection in NFs 
promotes actin microfilament reorganization and anchorage-independent growth, while 
Gal-3 transfection in fibrosarcoma cells promotes in vivo metastasis. NFs are 
differentiated into myofibroblasts (MyoF) upon treatment with exogenous Gal-3 or with 
TGF-β1 (in a Gal-3-dependent manner), promoting fibrosis. Under hypoxia, NFs up-
regulate Gal-3 in a HIF-1dependent fashion. Moreover, telomerase reverse 
transcriptase (TERT) transfection in NFs also up-regulates Gal-3, delaying senescence. 
 
Figure 3: Modulation of vascular and lymphatic endothelial cell signaling by 
galectins. A, Gal-1: Gal-1 directly binds to complex branched N-glycans on VEGFR2, 
and promotes VEGF-A-independent signaling. In tumors resistant to anti-VEGF 
treatment, vascular ECs display reduced α2,6 sialylation and increased N-glycan 
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branching, thus facilitating Gal-1 binding and angiogenesis. In contrast, in tumors 
sensitive to VEGF blockade, ECs show increased α2,6 sialylation, an effect that 
interrupts Gal-1 binding and inhibits vascularization. Blockade of Gal-1 or interruption 
of MGAT5-dependent N-glycan branching converted anti-VEGF resistant into anti-
VEGF sensitive tumors by attenuating compensatory angiogenesis. Moreover, Gal-1 
contributes to lymphangiogenesis by modulating LEC growth via specific interaction 
with VEGFR2. B, Gal-3: In vascular ECs, Gal-3 directly interacts with VEGFR2, 
inducing its phosphorylation and amplifying the angiogenic response to VEGF-A. Gal-3 
promotes clustering of VEGFR2 through binding to complex branched N-glycans 
generated by MGAT5. In the presence of Gal-3, VEGFR2 is retained on the EC surface 
and angiogenesis proceeds. C, Gal-8: Gal-8 controls LEC programs through binding to 
podoplanin (PDPN), β1 integrin and VEGFR3. In LECs, Gal-8 mediates 
lymphangiogenesis by interacting with PDPN and α1β1 or α5β1 integrins in a VEGFR3-
independent pathway. Additionally, Gal-8 promotes VEGF-C-induced 
lymphangiogenesis in vitro and in vivo through a VEGFR3-dependent pathway, in 
which PDPN/Gal-8/integrin interactions potentiate VEGF-C/VEGFR3 signaling. In 
vascular ECs, Gal-8 promotes angiogenesis in vitro and in vivo through binding to 
ALCAM (CD166). Abbrevaitions: α2,6 SA: α2,6-linked sialic acid; α2,3 SA: α2,3-
linked sialic acid. 
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Highlights 
 
-Galectins influence  tumor progression by reprogramming the tumor microenvironment 
-Galectins are expressed and released by both tumoral and non-tumoral cells  
-Galectins and glycans modulate fibroblast, endothelial and immune cell programs 
-Galectins control tumor immunity by targeting lymphoid and myeloid cell function 
 
 
